MedTrace Logo

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

NCT01000896 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2010-02-04

No results posted yet for this study

Summary

The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.

Conditions

  • Cancer
  • Non Small Cell Lung Cancer
  • Epithelial Ovarian Cancer

Interventions

DRUG

AZD0530

film coated tablet, PO, daily

DRUG

Carboplatin

intravenous, 3 weeks

DRUG

paclitaxel

intravenous, 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Mary Stuart · AstraZeneca

  • Takashi Seto, MD, PhD · National Hospital Organisation Kyushu Cancer Centre

  • Naoyuki Nogami, MD · National Hospital Organisation Shikoku Cancer Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-09-30
Completion
2011-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01000896 on ClinicalTrials.gov